SERPIND1 (Heparin Cofactor II) Drug Discovery Landscape & Assay Solutions
- By admin
- 25 Jul 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Thrombosis & Fibrosis Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SERPIND1 drug discovery, mechanism studies, and therapeutic validation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPIND1 Full-Length Recombinant Protein (Wild-Type & Mutant Panel). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation and conformational integrity. | View SERPIND1 Products |
| Gene Delivery | SERPIND1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (hepatocyte, endothelial, hepatic stellate cells). | View SERPIND1 Products |
| Benchmark Ab | Anti-SERPIND1 Reference Antibody (Conformation-Sensitive). Recombinant monoclonal for native vs. cleaved form detection; suitable for Western Blot, ELISA, neutralization assays. | View SERPIND1 Products |
| Validator | SERPIND1 siRNA Set. For knockdown verification and specificity controls in cell-based coagulation, hepatic, and fibrosis models. | View SERPIND1 Products |
| Related Target A | F2 (Thrombin / Prothrombin). Primary protease substrate; required for protein-protein interaction, inhibition kinetics, and activity assays. | View F2 Products |
| Related Target B | SERPINC1 (Antithrombin III). Parallel anticoagulant serpin; essential for off-target specificity counter-screening and selectivity assays. | View SERPINC1 Products |
| Related Target C | SERPINE1 (PAI-1). Complementary serpin in fibrinolysis regulation; relevant for fibrosis pathway analysis and combined mechanism studies. | View SERPINE1 Products |
| Related Target D | THBD (Thrombomodulin). Endothelial anticoagulant node; synergistic pathway partner for combined mechanism studies. | View THBD Products |
Critical Assay Challenges & Technical Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Serpin Conformational Integrity (Latent vs. Active vs. Cleaved) | HEK293 expressed with native glycosylation; Sequence-verified RCL (Reactive Center Loop) integrity; cleaved-form (RCL-inserted) variant available for structural comparison. |
| GAG Binding Specificity (Dermatan Sulfate vs. Heparin) | High-purity protein with verified disulfide bond formation for heparin-binding domain studies; tested binding kinetics via SPR/BLI. |
| Thrombin Inhibition Kinetics | Endotoxin-controlled (<1 EU/µg) suitable for primary cell co-culture assays; second-order rate constant determination. |
| Serpin Subfamily Cross-Reactivity (vs. SERPINC1, SERPINA1) | Homolog panel proteins (SERPINC1, SERPINA1, SERPINA10) strictly verified by mass spec for counter-screening. |
| Lack of Reliable Controls for Assay Standardization | Validated siRNA for target-specificity checks; benchmark reference antibody for assay standardization; sequence-verified recombinant positive controls. |
| Cross-species Preclinical Evaluation (Human / Mouse / Cyno) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity; endotoxin controlled to prevent confounding coagulation signals. |
| Endothelial Cell Model Validation False Positives | Valid sequence-targeted siRNA included for specificity checks in endothelial models. |
Key Genetic Mutations in SERPIND1
According to UniProt (P05546), three clinically relevant single nucleotide polymorphisms (SNPs) have been catalogued in dbSNP: rs5905 (VAR_011746), rs165867 (VAR_011747), and rs34324685 (VAR_051953). These mutations may affect the reactive center loop or glycosaminoglycan binding affinity, potentially altering thrombin inhibition efficiency and disease susceptibility. Researchers studying congenital HCII deficiency or thrombosis risk should consider these variants when designing functional assays or recombinant mutant panels.
Live SERPIND1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of SERPIND1 (Heparin Cofactor II) extends beyond traditional anticoagulation. As a serine protease inhibitor, it specifically inhibits thrombin in a dermatan sulfate-dependent manner, offering site-specific anticoagulation at vascular injury sites. Current R&D focuses on its role in congenital HCII deficiency, disseminated intravascular coagulation (DIC), sepsis, and emerging fibrotic diseases (liver/pulmonary fibrosis) through inhibition of chymases and cathepsins. The next wave of development includes recombinant protein replacement therapies for rare coagulopathies, gene therapy (liver-directed AAV/Lentivirus) for long-term correction, small molecule enhancers of GAG binding for targeted anticoagulation, and biomarker detection panels for hepatic function monitoring. The competitive landscape is niche but expanding, driven by the demand for safer, locally-acting anticoagulants.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein Replacement | Rare Disease Consortia, Academic Labs | Congenital HCII Deficiency, DIC, Preeclampsia | Activity Recovery Assay (need high-purity WT & mutant reference standards with native conformation) |
| Gene Therapy / Liver-Directed Expression | Gene Therapy Developers | Thrombophilia, Coagulopathy | Potency Assay (need full-length ORF Lentivirus for hepatic cell models) |
| Monoclonal Antibody / Mimetic | Diagnostic & Hematology Firms | Atherosclerosis Biomarker, Thrombosis Prevention | Epitope Mapping & Competitive Binding (need conformationally intact antigen) |
| Small Molecule / Peptide Modulator | Academic & Early Discovery | Cardiovascular Disease, Sepsis, Inflammation | Cofactor-Dependent Inhibition Assay (need native glycosylation, correctly folded protein with dermatan sulfate) |
| GAG Analog Modulators | Glycobiology Research Groups | Venous Thrombosis (Targeted) | Dermatan sulfate binding vs. Heparin binding assays |
| Biomarker Detection | Diagnostic Developers | Hepatic Function Monitoring | Conformation-specific antibody pairs (Native vs. Complexed) |
| Fibrosis Inhibitors | Specialty Biotech | Liver/Pulmonary Fibrosis | Protease inhibition panel (Chymase, Cathepsin G, Thrombin) |